Rapid Improvement of Depression of Fluoxetine Combined With ATP
NCT05431413, Phase 2, Unknown, Nanfang Hospital, Southern Medical University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Rapid Improvement of Depression of Fluoxetine Combined With ATP | ClinicalTrials.gov |
| NCT number | NCT05431413 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 195 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Nanfang Hospital, Southern Medical University | ClinicalTrials.gov |
| Conditions | Depression | ClinicalTrials.gov |
| Interventions | Control group: Fluoxetine and Placebo, Experimental group: Fluoxetine and ATP, Control group: Fluoxetine and Phosphocreatine | ClinicalTrials.gov |
| First posted | 2022-06-24 | ClinicalTrials.gov |
| Last updated | 2023-11-15 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Hamilton Depression Scale | Baseline and one, two, four weeks after treatment | Changes in Hamilton Depression Scale（HAMD-24） | ClinicalTrials.gov |
| Secondary | structural brain networks | Baseline and two, four weeks after treatment | Changes in diffusion tensor imaging（DTI）and Diffusion Spectral Imaging(DSI) | ClinicalTrials.gov |
| Secondary | functional brain networks | Baseline and two and four weeks after treatment | Changes in functional magnetic resonance imaging（fMRI）and quantitative susceptibility mapping(QSM） | ClinicalTrials.gov |
| Secondary | Hamilton Anxiety Scale | Baseline and one, two, four weeks after treatment | Changes in Hamilton Anxiety Scale（HAMA） | ClinicalTrials.gov |
| Secondary | Clinical Global Impression | Baseline and one, two, four weeks after treatment | Changes in Clinical Global Impression（CGI） | ClinicalTrials.gov |
| Secondary | Snaith-Hamilton Pleasure Scale | Baseline and one, two, four weeks after treatment | Changes in Snaith-Hamilton Pleasure Scale（SHAPS） | ClinicalTrials.gov |
| Secondary | Insomnia Severity Index | Baseline and one, two, four weeks after treatment | Changes in Insomnia Severity Index（ISI） | ClinicalTrials.gov |
| Secondary | Patient Health Questionnaire | Baseline and one, two, four weeks after treatment | Changes in Patient Health Questionnaire（PHQ-9） | ClinicalTrials.gov |
| Secondary | Columbia-Suicide Severity Rating Scale | Baseline and one, two, four weeks after treatment | Changes in Columbia-Suicide Severity Rating Scale（C-SSRS) | ClinicalTrials.gov |
| Secondary | Antidepressants Side Effects | Baseline and one, two, four weeks after treatment | Number of Participants with antidepressants side effects（SERS） | ClinicalTrials.gov |
| Secondary | C-reaction protein | Baseline and two and four weeks after treatment | Changes in C-reaction protein（CRP） | ClinicalTrials.gov |
| Secondary | Tumor Necrosis Factor α | Baseline and two and four weeks after treatment | Changes in Tumor Necrosis Factor（TNF-α） | ClinicalTrials.gov |
| Secondary | interleukin- 6 | Baseline and two and four weeks after treatment | Changes in interleukin- 6（IL-6） | ClinicalTrials.gov |
| Secondary | N-back task | Baseline and two and four weeks after treatment | Changes in reaction time and accuracy | ClinicalTrials.gov |
| Secondary | Stroop task | Baseline and two and four weeks after treatment | Changes in reaction time and accuracy | ClinicalTrials.gov |
| Secondary | Psychomotor vigilance task | Baseline and two and four weeks after treatment | Changes in reaction time and accuracy | ClinicalTrials.gov |
| Secondary | Attention network test | Baseline and two and four weeks after treatment | Changes in reaction time and accuracy | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| 1-Back Task | Secondary outcome | ConductCognition |
| 2-Back Task | Secondary outcome | ConductCognition |
| Attention Network Test | Secondary outcome | ConductCognition |
| Psychomotor Vigilance Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)